Patents should not put cancer care out of reach
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The recently released its Global Status Report on Cancer, highlighting staggering statistics and inherent inequities in access to care, particularly in low- and middle-income countries. This stark reality is echoed in India, where the standing committee has sought recommendations to improve affordability. An opinion piece underscores that the high cost of patented medicines like cancer drugs constitutes a violation of the constitutional right to health, highlighting the urgent need for India to leverage tools like to ensure life-saving treatments are accessible.
UPSC Perspectives
Polity
The issue of affordable healthcare is fundamentally rooted in the Indian Constitution. The has consistently interpreted the right to health as an integral part of the right to life enshrined under . This interpretation implies an obligation on the state to make essential medicines affordable and accessible. The article highlights that exorbitant pricing of life-saving patented medicines can be seen as a direct infringement on this fundamental right, as it effectively puts treatment out of reach for many. Litigation surrounding drug pricing and access, such as the In Re Exorbitant Pricing of Life Saving Patented Medicines case in the , highlights the ongoing struggle to balance intellectual property rights with the constitutional mandate for public health. UPSC often examines the interplay between fundamental rights and public policy, making this a critical case study on how courts interpret and enforce socio-economic rights in the face of market realities.
Economic
The high cost of cancer care underscores a significant market failure where the pricing of patented medicines is disconnected from affordability, particularly in a developing country like India. The provides mechanisms to address this, notably through (Sections 92 and 100), which allows the government to authorize a third party to make, use, or sell a patented product without the consent of the patent owner in situations of national emergency or extreme urgency. The article notes that despite aligning with the , India has only issued one compulsory license (for 's Nexavar in 2012). This highlights a hesitation to use available legal tools to counter monopolistic pricing practices. The on the TRIPS Agreement and Public Health explicitly states that intellectual property protection should not supersede public health needs. From an economic perspective, balancing the incentive for innovation (through patents) with ensuring access to essential goods (public health) is a central challenge in India's intellectual property regime.
Social
The WHO report's data on cancer survival rates reveals stark global and domestic health inequities. The disparity between survival rates in high-income versus low-income countries (87% vs. 42% for breast cancer) is not biological but systemic, driven by disparate access to diagnostics and priority medicines. In India, with over 15 lakh new cases expected in 2024, the late detection of cases (over half at an advanced stage) exacerbates the financial burden, as treatments become more expensive and less effective. This scenario highlights the socio-economic impact of disease, where catastrophic healthcare expenditure can push vulnerable populations deeper into poverty. The right to health is not merely a legal concept but a critical social determinant of well-being. A public health system's efficacy is measured by its ability to provide equitable access to care, making the affordability of cancer treatments a key metric of social justice and a vital issue in India's healthcare policy discourse.